- Home
- IMCC vs CANF Comparison
IMCC vs CANF Comparison
Compare IMCC & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- CANF
- Stock Information
- Founded
- IMCC 1980
- CANF 1994
- Country
- IMCC Israel
- CANF Israel
- Employees
- IMCC N/A
- CANF N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- CANF Health Care
- Exchange
- IMCC Nasdaq
- CANF Nasdaq
- Market Cap
- IMCC 11.8M
- CANF 13.5M
- IPO Year
- IMCC N/A
- CANF N/A
- Fundamental
- Price
- IMCC $2.81
- CANF $0.98
- Analyst Decision
- IMCC
- CANF Strong Buy
- Analyst Count
- IMCC 0
- CANF 2
- Target Price
- IMCC N/A
- CANF $14.00
- AVG Volume (30 Days)
- IMCC 75.2K
- CANF 110.7K
- Earning Date
- IMCC 08-13-2025
- CANF 08-29-2025
- Dividend Yield
- IMCC N/A
- CANF N/A
- EPS Growth
- IMCC N/A
- CANF N/A
- EPS
- IMCC N/A
- CANF N/A
- Revenue
- IMCC $37,894,737.00
- CANF $674,000.00
- Revenue This Year
- IMCC $47.12
- CANF $461.72
- Revenue Next Year
- IMCC $12.83
- CANF N/A
- P/E Ratio
- IMCC N/A
- CANF N/A
- Revenue Growth
- IMCC 12.68
- CANF N/A
- 52 Week Low
- IMCC $1.29
- CANF $0.97
- 52 Week High
- IMCC $7.12
- CANF $3.92
- Technical
- Relative Strength Index (RSI)
- IMCC 46.59
- CANF 31.61
- Support Level
- IMCC $2.90
- CANF $1.00
- Resistance Level
- IMCC $3.21
- CANF $1.05
- Average True Range (ATR)
- IMCC 0.34
- CANF 0.02
- MACD
- IMCC -0.07
- CANF -0.00
- Stochastic Oscillator
- IMCC 5.05
- CANF 12.50
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).